ReviewFrontiers in immunology2021
Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 58 citations in OpenAlex.
- Tumor cell membrane‑coated MOF‑199 nanoparticles co‑loaded with auranofin and celecoxib enhance single‑dose radiotherapy and anti‑PD‑L1 therapy in cervical cancer.Journal of nanobiotechnology · 2026Article
- Review
- Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy.Nature communications · 2026Article
- GM-CSF Armed Oncolytic Adenovirus Enhances T-Cell Infiltration and Suppresses Local and Distal Tumor Growth.Viruses · 2026Article
- Decoding the spatiotemporal dynamics of tumor immune niche remodeling in cancer immunotherapy.Frontiers in immunology · 2026Review
- Progress in the research and development of oncolytic virus therapies.Frontiers in pharmacology · 2026Review
- Recent advances in preclinical studies combining hyperthermia therapy with novel immune checkpoint targeting agents.Frontiers in immunology · 2026Review
- Targeting Tumour Heterogeneity through sequential timing of anti-hallmark combination therapies -a hypothesis for implementation.Frontiers in immunology · 2026Review
- Developing of potential mRNA vaccines based on tumor antigens and immune subtypes of esophageal cancer.Translational cancer research · 2025Article
- Oncolytic viruses as anticancer agents: clinical progress and remaining challenges.Lancet (London, England) · 2025Review
- Endoscopic Ablation in Cholangiocarcinoma.Cancers · 2025Review
- Review
- Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack.Immunotherapy · 2025Review
- The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Differential effects of small extracellular vesicles from head and neck cancer patients on dendritic cell functions.Frontiers in oncology · 2025Article
- A Critical Role of DC-SIGNImmunoTargets and therapy · 2025Article
- Experimental models for developing oncolytic virotherapy for metastatic prostate cancer.Frontiers in immunology · 2025Review
- Cytokine-based immunotherapy for gastric cancer: targeting inflammation for tumor control.Exploration of targeted anti-tumor therapy · 2025Review
- Exploring the Link Between Obligate Anaerobe-Related Dysbiosis and Prostate Cancer Development: A Pilot Study.Cancers · 2024Article
- Glutathione Peroxidases: An Emerging and Promising Therapeutic Target for Pancreatic Cancer Treatment.Antioxidants (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Cancer patients with low or absent pre-existing anti-tumour immunity ("cold" tumours) respond poorly to treatment with immune checkpoint inhibitors (ICPI). In order to render these patients susceptible to ICPI, initiation of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.